Pyrroloquinoline Quinone Disodium Salt

Pyrroloquinoline Quinone Disodium Salt, commonly known as PQQ, is a redox-active quinone molecule that has attracted commercial interest for its role in supporting mitochondrial function and cellular energy metabolism. It is not a vitamin or mineral but is classified as a novel functional compound. In the EU, PQQ is under novel food assessment and does not carry authorised health claims under Reg. (EU) 432/2012. Brands use it as a premium ingredient for positioning around mitochondrial health, cognitive vitality, and healthy ageing.

For private-label gummy manufacturers, PQQ offers good applicability due to its heat stability and solubility in gummy matrices. Its premium cost tier positions it for high-value product ranges targeting consumers interested in energy, cognitive function, and longevity. Because no EU-authorised claims exist for PQQ, any claim coverage must come from co-formulated nutrients with authorised claims, such as Vitamin B6 or Magnesium for nervous-system function, or Vitamin C for antioxidant protection.

Origin and history

Pyrroloquinoline Quinone was first identified in 1979 as a novel redox cofactor in bacteria. It was later found to be present in small amounts in various foods, including fermented soybeans, green tea, and certain fruits and vegetables. Its biological significance in mammals was established through research demonstrating its role in mitochondrial biogenesis and cellular energy production. Commercial interest in PQQ as a dietary supplement ingredient grew in the early 2000s, particularly in the US and Asian markets.

Industrial production of PQQ disodium salt is achieved through chemical synthesis or microbial fermentation. The disodium salt form is the most common commercial variant due to its improved stability and solubility compared to the free acid form. In the EU, PQQ is classified as a novel food ingredient and is subject to pre-market authorisation under Regulation (EU) 2015/2283. As of the current date, it remains under assessment, meaning it cannot be marketed as a food supplement ingredient in the EU without authorisation.

Scientific overview

PQQ functions primarily as a redox cofactor, participating in electron transfer reactions within cells. Its most studied biological role is the stimulation of mitochondrial biogenesis — the process by which new mitochondria are formed within cells. This is mediated through the activation of the PGC-1α pathway, a key regulator of mitochondrial function. PQQ also exhibits antioxidant properties, protecting cells from oxidative stress by scavenging reactive oxygen species. These mechanisms underpin its positioning for energy metabolism, cognitive function, and healthy ageing.

Bioavailability of PQQ disodium salt is moderate, with oral administration leading to measurable plasma levels in human studies. The compound is absorbed in the small intestine and distributed to tissues including the brain, liver, and kidneys. The disodium salt form offers improved solubility and stability compared to the free acid, making it the preferred form for supplement manufacturing. Typical human studies use doses ranging from 10–20 mg per day.

From a manufacturing perspective, PQQ is heat-stable and soluble in gummy matrices, which simplifies formulation. Its premium cost tier means it is typically used at low doses (10–20 mg per serving) to manage cost per unit. No specific formulation conflicts or synergies have been documented in the available data, but DAT reviews these per project. Standard processing conditions apply, and no special handling is required beyond standard good manufacturing practices.

Brands use PQQ in gummies to target the growing consumer interest in mitochondrial health, cellular energy, and healthy ageing. It is one of the most familiar and commercially understood novel functional compounds across EU and US markets. Its premium positioning allows brands to differentiate their product ranges and command higher price points. Common positioning angles include mitochondrial biogenesis, cognitive vitality, energy metabolism, and antioxidant support. Because no EU-authorised health claims exist for PQQ, brands must rely on co-formulated nutrients with authorised claims or use non-health claims such as "with PQQ" or "supports mitochondrial function" (where permitted under local regulations).

From a formulation and manufacturing standpoint, PQQ is well-suited to gummy production. It is heat-stable, soluble, and does not require special processing conditions. Its premium cost tier means it is typically used at low doses, which helps manage cost per unit. The absence of documented taste issues simplifies flavour masking. DAT confirms the final dosage, form, and stability per project after reviewing the target claim, market, and regulatory status.

For pack copy, brands must exercise strict claim discipline. No disease claims are permitted. No "anti-inflammatory" language is allowed in EU pack copy. No certification promises (vegan, kosher, halal, organic, non-GMO) can be made on pack until confirmed per project and batch documentation. No guaranteed shelf-life can be stated until confirmed with stability data. DAT reviews all claims per project and confirms regulatory compliance before final label approval.